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The role of the expiratory phase in obstructive 
sleep apnoea 
0. RESTA, P. GUIDO, V. PICCA, F. SCARPELLI AND M. P. FOSCHINO 
Center of Sleep Respiratory Disease, Don Uva Institute, Bisceglie, Chair of Respiratory Disease, 
University of Bari, Italy 
The role of the expiratory phase in obstructive sleep apnoea (OSA) is not well known. The aim of our study was to 
verify the contribution of expiratory narrowing to apnoea in a group of OSA patients by evaluating the effects of 
short-term treatment with continuous positive airway pressure (CPAP), intermittent positive pressure ventilation 
(IPPV) and bi-level positive airway pressure (BIPAP). 
We studied a selected group of 10 OSA patients whose therapeutic pressure level of CPAP was at least 10 cm H,O. 
During CPAP therapy the mean apnoealhypopnoea index (AHI) and oxyhaemoglobin desaturation index (ODI) 
decreased from 64.8 to 6.3 (P<O.OOl) and from 58.5 to 6.1 (P<O.OOl), respectively and mean nadir SAO, increased 
from 62.0 to 91.6 (P<O.OOl). 
None of the patients reached optimal setting (elimination of snoring, reduction of apnoeas and non-apnoeic 
desaturation events at least to 15 or less per hour of sleep and maintenance of oxygen saturation approximately 90%) 
during IPPV and two patients did not tolerate final IPAP pressure levels. When a critical level of EPAP (BIPAP) was 
applied in the same night to these patients, optimal setting was reached in all subjects. During BIPAP, mean AH1 
decreased from 64.8 to 7.4 (P~O.001); ODI decreased from 58.5 to 7.6 (P<O.OOl) and nadir SAO, increased from 
62.0 to 91.2 (P<O.OOl). 
Our study confirms the essential role of a critical level of EPAP in successful ventilatory treatment in OSA, thereby 
indicating, in agreement with few previous studies, the critical role of end of expiratory occlusion in OSA 
pathogenesis. 
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Introduction 
Continuous positive airway pressure (CPAP) is the most 
effective non-surgical method available for reversing upper 
airway occlusion during sleep in patients with obstructive 
sleep apnoea (OSA) (1,2). CPAP is believed to act by 
splinting the upper airways open, but a role in increasing 
the functional residual capacity (FRC) with subsequent 
pharynx opening has also been postulated (3,4). In 1983, 
Mahadevia et al. (5) studied the effects of an expiratory 
positive pressure valve in sleep apnoea and suggested that 
airway closure could take place during the expiratory phase 
independently of the favouring collapsing effect of negative 
inspiratory pressure. 
Studies by Sanders et a[. (6,7) support the hypothesis that 
expiratory phase events are important in the pathogenesis 
of OSA, with airway narrowing at the end of expiration, 
perhaps setting the stage for total occlusion with generation 
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of sub-atmospheric intrapharyngeal pressure during the 
ensuing inspiratory effort. Consequently, the effectiveness 
of CPAP in OSA could be due both to an expiratory effect 
(i.e. preventing total or near total closure at end expiration) 
and to an inspiratory effect (i.e. preventing the exaggeration 
of pharyngeal narrowing and/or closure by the inspiratory 
negative intraluminal pressure). 
In relation to the differing roles of and contribution of 
expiration and inspiration to airway collapse during sleep in 
OSA patients, a bi-level positive airway pressure device 
(BIPAP Respironics Inc, Monroeville, PA, U.S.A.) has 
been developed that allows independent adjustment of 
inspiratory and expiratory pressures with the possibility of 
treating OSA patients with two different pressure levels. 
Sanders et al. (8) have shown that with optimal setting of 
inspiratory positive airway pressure (IPAP) and expiratory 
positive airway pressure (EPAP) by BIPAP, obstructive 
sleep breathing disorders can be eliminated at lower levels 
of expiratory air pressure. Under these conditions, the 
application of EPAP at a critical pressure level, preventing 
airway occlusion during end expiration, could allow for 
sufficient subsequent inspiratory efforts to trigger IPAP, 
with resulting disappearance of apnoeas in the BIPAP 
mode. 
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The aim of our study was to verify the contribution of 
expiratory narrowing to apnoea in a group of OSA 
patients, with nightly evaluation of the effects of short-term 
treatment with CPAP, with IPAP alone (intermittent posi- 
tive pressure ventilation; IPPV), or with IPAP and EPAP 
(BIPAP). 
Materials and Methods 
We studied a group of 10 OSA patients selected on the basis 
of a therapeutic CPAP pressure level of at least 10 cm H,O. 
Patients were recruited for the study from a group of 80 
OSA patients who had been referred to our Centre during a 
period of 1 year. The selection criteria were: presence of 
severe OSA (AH1 >40 h - i) with at least 85% of obstructive 
events; consensus to the ventilation treatment; therapeutic 
CPAP pressure level of at least 10 cm H,O; no history or 
clinical evidence of primary central nervous system dys- 
function, primitive cardiac disease or neuromuscular dis- 
ease; no presence of right heart failure or respiratory 
failure; no pulmonary disease; no previous ventilatory 
treatment; no drug therapy; and no alcohol abuse. Prior to 
initiating the study patients were informed about the 
research protocol, and written consent was obtained. 
Patients were selected after a full night basal polysomnog- 
raphy (PSG,) without ventilatory support. Following PSG, 
the patients were given the opportunity to become familiar 
with ventilatory support and various nasal interfaces 
including masks and prongs. Subsequently patients were 
submitted to overnight CPAP titration (PSG,). In the 
subsequent night, following CPAP administration at the 
previously determined therapeutic level for about 30 min of 
sleep to stabilize the ventilatory pattern of the subject, we 
reduced EPAP level to the minimum (about 2 cm H,O) in 
order to administer IPAP-only treatment (IPPV). There- 
after, EPAP was increased until breathing was normal, or 
the previously determined CPAP level was attained. 
During PSG the electroencephalogram (EEG) (two 
leads), electro-oculogram (EOG) (two leads), submental 
electromyogram (EMG), and electrocardiogram (ECG) 
readings were recorded continuously with surface elec- 
trodes in the standard fashion (9). Airflow was qualitatively 
recorded by thermocouples at the nose and mouth, and 
quantified by a pneumotacograph system connected to the 
nasal mask. Ribcage and abdominal ventilatory movements 
were also recorded continuously using respiratory induct- 
ance plethysmography, with oxyhaemoglobin saturation 
recorded by pulsoximetry (Nellcor, Puritan Bennet) and 
end tidal CO, recorded by capnography (Nellcor). Snoring 
was recorded by a microphone attached to the neck. Mask 
pressure was continuously recorded during PSG, with 
CPAP, IPPV and BIPAP. All sleep data were recorded 
continuously on a multichannel polygraph recorder (Respi- 
somnographe, Sefam, Nancy, France; Knightscan software 
Version 1.80). Sleep stage was determined by the criteria of 
Rechtschaffen and Kales (9). 
In all patients the three ventilatory modes, CPAP, IPPV, 
and BIPAP, were administered using a BIPAP SIT 
Respironics device in the spontaneous mode (S-mode). 
Nasal CPAP was titrated by increasing pressure from an 
initial level of 2.5 cm H,O, in increments of 2.5 cm H,O to 
reach a therapeutic effect at a level sufficient to achieve the 
optimal setting of eliminating snoring, reducing apnoeas 
and non-apnoeic desaturation events to at least 15 or less 
per hour of sleep, and maintaining oxygen saturation at 
approximately 90%. IPPV was administered by progres- 
sively increasing IPAP until the therapeutic CPAP value, or 
the maximum level tolerated, was reached. Finally, while 
the same IPAP pressure level was maintained, we applied 
EPAP in increasing amounts until the optimal setting was 
obtained. 
DATA ANALYSIS 
In our study we considered apnoeas (cessation of airflow 
for at least 10 s); hypopnoeas (defined as non-apnoeic 
events, associated with a reduction in SAO, by at least 4%, 
which is more readily evaluated during CPAP than simple 
airBow decrease, and represents obstructive hypopnoeas); 
the apnoeaJhypopnoea index, AH1 (number of events per 
hour of sleep); the oxyhaemoglobin desaturation index, 
ODI (number of desaturation reduced events by at least 4% 
per hour of sleep); and the lowest nocturnal oxyhaemo- 
globin saturation, nadir. Because almost all events in our 
patients were obstructive (apnoic or non-apnoeic events 
with the presence of ventilatory effort), no distinction was 
made in the analysis between the specific patterns of each 
apnoea. 
Data are given as mean (SD). Statistical comparisons were 
performed using the Student’s paired t-test with PcO.05 
judged to be statistically significant. 
Results 
The study was performed in nine men and one woman in 
whom OSA had been diagnosed. Anthropomorphic char- 
acteristics, pulmonary function and parameters of gas 
exchange are shown in Table 1. The mean age (SD) of the 
group was 45.4 (14.4) years, with a mean body mass index 
(BMI) of 36.7 (9.5) kg m - 2. All the patients were normoxic 
and normocapnic. No patients had an obstructive ventila- 
tory defect (FEVJFVC ~70%). All patients had predomi- 
nantly obstructive sleep apnoea on PSG, (more than 90% 
of events were mixed or obstructive), with a mean AH1 of 
64.8 (15.1) (range 43-83), a mean ODI of 58.5 (13.8) (range 
40-75) and a mean nadir of 62.0% (14.0) (range 31-76). 
Sleep period time (SPT) was 93.4% of total sleep time 
(TST), stages I-II NREM sleep were 79% of SPT, stages 
III-IV were 2% and REM sleep was 11%. 
According to protocol, therapeutic CPAP pressure was at 
least 10 cm H,O [mean 11.6 (2.6) cm H,O; range 10-181. 
The effects of the three ventilatory modes on breathing and 
oxygenation during sleep are shown in Table 2 and Fig. 1. 
During CPAP therapy, mean AH1 and ODI decreased, 
respectively, from 64.8 to 6.3 (P<O*OOl) and from 58.5 to 
6.1 (P<O.OOl), and mean nadir increased from 62.0 to 91.6 
(P<O.OOl). Stages I-II NREM sleep decreased to 50% of 
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TABLE 1. Mean (SD) anthropomorphic characteristics, pulmonary functions and parameters of gas 
exchange of 10 patients 
Sex Age BMI FEV, FVC FEVJFVC PA& PACO, 
WF) (years) (kg m - *) (% pred.) (% pred.) (“W (mm&) (mmW 
911 454 (14.4) 36.7 (9.5) 77.4 (13.7) 75.3 (13.0) 86.5 (6.7) 82.0 (13.2) 38.8 (2.9) 
SPT and stages III-IV increased to 26%, while REM sleep 
increased to 16%. 
During IPPV, sleep-related disordered breathing per- 
sisted in all patients, either because patients did not tolerate 
the highest pressure level (two patients), or because IPAP 
alone was unable to suppress completely apnoeic and 
hypopnoeic events. The mean IPAP level pressure was 12.7 
(2.6) cm H,O. In three patients we were able to increase 
IPAP pressure above the therapeutic CPAP level. During 
this ventilatory treatment, AH1 decreased from 64.8 to 45.0 
(P<O.O5), ODI decreased from 58.5 to 41.3 (PcO.05) and 
nadir increased from 62.0 to 80.6 (PcO.01). In all patients 
we observed that virtually all apnoeas were associated with 
failure of patients to trigger IPAP, even if IPAP had 
increased above therapeutic pressure levels (Figs 2 and 3). 
When EPAP (BIPAP) was administered in these patients 
with unchanged IPAP pressure, apnoeas were eliminated at 
a critical EPAP level specific to each patient (Fig. 3). 
SPT decreased to 70%, stages I-II, NREM sleep 
decreased to 70%, stages III-IV were 2% and REM sleep 
was 8% of SPT. 
During BIPAP optimal setting was reached in all 
patients, with mean IPAP value at 12.7 (2.6) cm H,O, and 
mean EPAP level at 8.2 (2.4) cm H,O. During BIPAP, AH1 
decreased from 64.8 to 7.4 (P<O.OOl), ODI decreased from 
58.5 to 7.6 (P<O.OOl) and nadir increased from 62.0 to 91.2 
(PCO.001). 
In spite of the lower EPAP, compared to CPAP, pressure 
(8.2 vs. 11.6; P<O.OOl) BIPAP was as effective as CPAP in 
reducing total AH1 (7.4 vs. 6.3; P=n.s.), ODI (7.6 v,s. 6.1; 
P=n.s.) and nadir (90.9 vs. 91.6; P=n.s.). 
During BIPAP application stages I-II NREM sleep were 
present during 50% of the SPT, stages III-IV during 25% 
and stage REM sleep during 15%. 
While there was a greater SPT on the final optimal setting 
during CPAP application compared with BIPAP, there was 
no difference with respect to the time spent in the NREM 
and REM stages as percentages of the SPT. The sleep 
efficiency during IPPV was lower than during CPAP 
or BIPAP application and was associated with many 
arousals and with a less-rested patient. 
Discussion 
It is currently believed that obstructive apnoeas are due to 
collapse of the upper airway (UA), secondary to negative 
intraluminal pressure generated by the inspiratory muscles, 
during inspiration in patients with inherent instability of 
this upper airway (10-13). 
Sanders and Moore (6) however, have found that, in 
patients with OSA, not only inspiratory but also expiratory 
airway resistance increase during sleep, thus suggesting that 
UA obstruction is not limited to inspiration. 
More recently, some reports (8,14-17) using different 
methods have suggested the occurrence of end-expiratory 
upper airway narrowing in patients with OSA, suggesting 
that a critical level of expiratory positive airway pressure 
is essential for uninterrupted upper airway patency 
during sleep. This is in keeping with previous findings by 
Mahadevia et al. (5), who reported that 10 cm H,O of 
expiratory positive airway pressure significantly reduced the 
frequency and duration of apnoeas along with the degree of 
nocturnal oxygen desaturation. 
Our study, which is based on the different response 
during sleep of OSA patients to short-term application of 
CPAP, IPPV and BIPAP, supports these previous findings 
and shows the importance of expiratory events in the 
pathogenesis of obstructive sleep apnoea. OSA is not 
an ‘inspiratory’ problem, therefore, but an expiratory- 
inspiratory phenomenon. Indeed, we have shown that 
if a sufficiently high pressure is not applied during 
expiration, the patient is unable to trigger inspiratory 
airflow during the following inspiration even in the presence 
of high inspiratory pressure, as seen in the IPPV mode 
and in the BIPAP mode when EPAP was below the 
optimal level. 
Considering that the trigger for IPAP in this type of 
device is possible with a low inspiratory flow, it is unlikely 
that failed triggers were due to a too-low trigger sensibility. 
On the contrary, it seems likely that inspiratory flow 
generation and the IPAP trigger are impossible to achieve 
due to UA end exipiratory occlusion, strongly suggesting 
that the airway narrows andlor occludes during expiration, 
prior to the appearance of the negative inspiratory 
intraluminal pressure. 
When EPAP (BIPAP) was applied at the critical pressure 
level under these conditions, sufficient to maintain UA 
patency during expiration, the patient was able to generate 
an inspiratory flow to trigger IPAP. This, if adequate, 
overcame the collapsing influence of sub-atmospheric intra- 
luminal pressure, thereby avoiding inspiratory occlusion 
and apnoea and maintaining airway patency throughout 
the remainder of inspiration. The situation is probably 
more complex due to the role of other forces, such as 
mucosal adhesion surface forces which have not yet been 
well studied. That a more complex mechanism is involved is 
suggested by the fact that once a critical EPAP level is 
achieved, as shown in Fig. 3, three to four breaths were 
necessary before thoraco-abdominal paradoxic breathing 
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Basal CPAP IPPV BIPAP 
FIG. 1. Apnoealhypopnoea index (AHI) during basal 
PSG (PSG,), without ventilatory support and in the sub- 
sequent nights during treatment with CPAP, IPPV, 
BIPAP. The obtained values for each treatment were 
compared with values recorded in PSG,: *P<O.O5; 
**P<O.Ol; ***P<O.OOl. Data area means; error bars 
show SD. 
Time (60 s) 
‘22: 
I , 
SAO, 
Ribcage 
Abdomen 
Flow 
FIG. 2. Representative trace demonstrating failure of 
patient to trigger IPAP, with persisting apnoea during 
application of IPPV. IPAP= 10 cm H,O. 
disappeared totally and breathing became regular and 
normal. 
Moreover, we have reinforced the concept that successful 
IPAP triggering and apnoea elimination occurred only 
when EPAP reached a critical level, specific to each patient. 
Even though the IPAP pressure level during BIPAP was 
pre-established according to protocol, we have confirmed 
the experience of others (8) that effective treatment of 
obstructive breathing disorders may be achieved with lower 
levels of positive pressure during expiration than inspira- 
tion and at a lower pressure than used in conventional 
CPAP. 
Finally, during IPPV with IPAP alone we observed a 
decrease of AH1 and ODI and, in particular, an increase of 
nadir, due to IPAP-induced reduction of non-apnoeic 
desaturation events (8). Consequently, it is possible to 
deduce from our study that, during these non-apnoeic 
desaturation events (attributable to obstructive hypopnoeas 
in patients affected by simple OSA), IPAP is triggered 
because of airway patency persisting at sufficient levels at 
the end of expiration. Montserrat (18), utilizing the forced 
oscillation technique, has recently reported that in most 
Time(60 s) I 
-EEG 
+EOG 
rEMG 
- /--+A& 
Ribcage 
--“(/jni?mIph 12 cm Hz0 
(a) (b) EPAP 6 cm Hz0 
FIG. 3. In the same patient as in Fig. 2: (a) trace demon- 
strating failure of the patient to trigger IPAP with persist- 
ence of obstructive apnoea, by increasing IPAP 
(12 cm H,O), during IPPV; (b) trace demonstrating elimi- 
nation of apnoea, unchanged IPAP (12 cm H,O) by 
administering a critical level of EPAP (6 cm H,O) during 
application of BIPAP. Note that after the EPAP of 
6 cm H,O is reached, partial paradoxic thoraco- 
abdominal breathing persists for four high-amplitude 
breaths until tidal volume decreases towards normal 
values and the paradox disappears. 
patients the beginning of an apnoea is preceded by brief 
obstruction, mainly during expiration, while during hypop- 
noeas, obstructive periods are mainly inspiratory. The 
significance of these observations, however, requires further 
investigation. 
In conclusion, these findings indicate that loss of airway 
patency in patients with OSA during sleep is not exclusively 
an inspiratory phenomenon and that end-expiratory occlu- 
sion is critical in OSA pathogenesis. Furthermore, our 
study confirms the essential role of a critical level of 
expiratory positive airway pressure in successful ventilatory 
treatment in patients with OSA. 
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